Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.44 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.33 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2526251 | 0.91 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL121731 | 0.87 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL8941498 | 0.87 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL1532519 | 0.87 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL28250490 | 0.85 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL28358233 | 0.85 | SLC28A1 (0.42) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL3827548 | 0.85 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL6879975 | 0.85 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL6389231 | 0.84 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL9644061 | 0.84 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0948256-A4 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | UNIV WASHINGTON (US) | 2007-10-24 | — | — | EP | claimed |
| US-6887707-B2 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | UNIVERSITY OF WASHINGTON (US) | 2005-05-03 | — | — | US | claimed |
| US-20030119764-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-26 | — | — | US | claimed |
| EP-0948256-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1999-10-13 | — | — | EP | claimed |
| WO-1998018324-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1998-05-07 | — | — | WO | claimed |
| US-20240052357-A1 | AUTONOMOUS INDUCIBLE DIRECTED EVOLUTION OF COMPLEX PATHWAYS | NORTH CAROLINA STATE UNIVERSITY | 2024-02-15 | — | — | US | disclosed |
| EP-1576154-B8 | IN VIVO AFFINITY MATURATION SCHEME | ANAPTYSBIO INC (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-1576154-B1 | IN VIVO AFFINITY MATURATION SCHEME | QUINTAIN CONSULTING PTY LTD (AU) | 2011-02-23 | — | — | EP | disclosed |
| US-20090311710-A1 | MUTAGENESIS METHODS USING RIBAVIRIN AND/OR RNA REPLICASES | COIA GREGORY | 2009-12-17 | — | — | US | disclosed |
| WO-2009043096-A1 | IMPROVED METHOD FOR MUTAGENESIS | ARANA THERAPEUTICS (VIC) PTY LTD (AU) | 2009-04-09 | — | — | WO | disclosed |
| EP-0948256-A4 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | UNIV WASHINGTON (US) | 2007-10-24 | — | — | EP | disclosed |
| EP-1558745-A4 | MUTAGENESIS METHODS USING RIBAVIRIN AND/OR RNA REPLICASES | EVOGENIX PTY LTD (AU) | 2006-08-30 | — | — | EP | disclosed |
| EP-1558745-A1 | MUTAGENESIS METHODS USING RIBAVIRIN AND/OR RNA REPLICASES | Evogenix Pty Ltd (AU) | 2005-08-03 | — | — | EP | disclosed |
| US-6887707-B2 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | UNIVERSITY OF WASHINGTON (US) | 2005-05-03 | — | — | US | disclosed |
| WO-2004055182-A1 | IN VIVO AFFINITY MATURATION SCHEME | DIATECH PTY LTD (AU) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004039995-A1 | MUTAGENESIS METHODS USING RIBAVIRIN AND/OR RNA REPLICASES | EVOGENIX PTY LTD (AU) | 2004-05-13 | — | — | WO | disclosed |
| US-20030148267-A1 | Screening assay for hepatitis C virus antiviral agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-08-07 | — | — | US | disclosed |
| US-20030119764-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-26 | — | — | US | disclosed |
| EP-0948256-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998018324-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1998-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119764-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | SAMHD1, BCDIN3D, DCTD | SLC28A1 891/4885SLC28A2 952/4885SLC29A1 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.